Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations

[1]  P. Lienau,et al.  Quantitation of Lysosomal Trapping of Basic Lipophilic Compounds Using In Vitro Assays and In Silico Predictions Based on the Determination of the Full pH Profile of the Endo-/Lysosomal System in Rat Hepatocytes , 2018, Drug Metabolism and Disposition.

[2]  A. Urtti,et al.  Melanin targeting for intracellular drug delivery: Quantification of bound and free drug in retinal pigment epithelial cells , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[3]  J. Wiśniewski,et al.  Intracellular Drug Bioavailability: Effect of Neutral Lipids and Phospholipids. , 2018, Molecular pharmaceutics.

[4]  M. Hann,et al.  Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery , 2017, Proceedings of the National Academy of Sciences.

[5]  P. Artursson,et al.  Intracellular drug bioavailability: a new predictor of system dependent drug disposition , 2017, Scientific Reports.

[6]  Yuan Chen,et al.  Evaluation of Cytochrome P450 3A4-Mediated Drug–Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation , 2016, Clinical Pharmacokinetics.

[7]  P. Nordlund,et al.  CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil , 2016, Nature Communications.

[8]  P. Jasper,et al.  Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1–Transfected Human Embryonic Kidney 293 Cells , 2016, Drug Metabolism and Disposition.

[9]  T. R. Johnson,et al.  Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model , 2015, Drug Metabolism and Disposition.

[10]  P. Mackenzie,et al.  Suppression of Cytochrome P450 3A4 Function by UDP-Glucuronosyltransferase 2B7 through a Protein-Protein Interaction: Cooperative Roles of the Cytosolic Carboxyl-Terminal Domain and the Luminal Anchoring Region , 2015, Molecular Pharmacology.

[11]  W. Zhou,et al.  Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam , 2015, Journal of clinical pharmacology.

[12]  Dan Fu,et al.  Imaging the Intracellular Distribution of Tyrosine Kinase Inhibitors in Living Cells with Quantitative Hyperspectral Stimulated Raman Scattering , 2014, Nature chemistry.

[13]  P. Artursson,et al.  A High-Throughput Cell-Based Method to Predict the Unbound Drug Fraction in the Brain , 2014, Journal of medicinal chemistry.

[14]  J Snoeys,et al.  Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug , 2014, Clinical pharmacology and therapeutics.

[15]  Li Liu,et al.  A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  K. Brouwer,et al.  Determination of Intracellular Unbound Concentrations and Subcellular Localization of Drugs in Rat Sandwich-Cultured Hepatocytes Compared with Liver Tissue , 2013, Drug Metabolism and Disposition.

[17]  Masoud Jamei,et al.  Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. , 2013, Journal of pharmaceutical sciences.

[18]  Per Artursson,et al.  Rapid measurement of intracellular unbound drug concentrations. , 2013, Molecular pharmaceutics.

[19]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[20]  T. R. Johnson,et al.  Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes , 2013, Drug Metabolism and Disposition.

[21]  J. Krise,et al.  Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications , 2012, Expert opinion on drug metabolism & toxicology.

[22]  S. Wrighton,et al.  Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions , 2012, Drug Metabolism and Disposition.

[23]  L Zhang,et al.  Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time‐Dependent CYP3A Inhibitor , 2012, Clinical pharmacology and therapeutics.

[24]  A. Galetin,et al.  Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction , 2012, Pharmaceutical Research.

[25]  Shiew-Mei Huang,et al.  Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation , 2012, Journal of clinical pharmacology.

[26]  R. Larson,et al.  Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase , 2011, European Journal of Clinical Pharmacology.

[27]  John A Wagner,et al.  Effect of Different Durations and Formulations of Diltiazem on the Single‐Dose Pharmacokinetics of Midazolam: How Long Do We Go? , 2011, Journal of clinical pharmacology.

[28]  Aleksandra Galetin,et al.  Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs , 2011, Drug Metabolism and Disposition.

[29]  M. Jamei,et al.  Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  Yvonne Will,et al.  A high content screening assay for identifying lysosomotropic compounds. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[31]  Ulf Bredberg,et al.  Measurement of Unbound Drug Exposure in Brain: Modeling of pH Partitioning Explains Diverging Results between the Brain Slice and Brain Homogenate Methods , 2011, Drug Metabolism and Disposition.

[32]  A. Suttle,et al.  An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors , 2010, Clinical pharmacology and therapeutics.

[33]  Michael Gertz,et al.  Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.

[34]  Masoud Jamei,et al.  Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  Bryan M. Li,et al.  Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. , 2009, Journal of medicinal chemistry.

[36]  Sara K Quinney,et al.  Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite , 2009, Drug Metabolism and Disposition.

[37]  E. Merkle,et al.  Phase I Trial of Pazopanib in Patients with Advanced Cancer , 2009, Clinical Cancer Research.

[38]  B. Geoerger,et al.  Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults , 2008, Clinical Cancer Research.

[39]  Aleksandra Galetin,et al.  Methods for predicting in vivo pharmacokinetics using data from in vitro assays. , 2008, Current drug metabolism.

[40]  Tristan S. Maurer,et al.  A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro , 2008, Drug Metabolism and Disposition.

[41]  Masoud Jamei,et al.  Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.

[42]  K. Ohashi,et al.  Effect of the Treatment Period With Erythromycin on Cytochrome P450 3A Activity in Humans , 2007, Journal of clinical pharmacology.

[43]  M. Correia,et al.  Endoplasmic Reticulum-Associated Degradation of Cytochrome P450 CYP3A4 in Saccharomyces cerevisiae: Further Characterization of Cellular Participants and Structural Determinants , 2006, Molecular Pharmacology.

[44]  E. Jonsson,et al.  BRAIN DISTRIBUTION OF CETIRIZINE ENANTIOMERS: COMPARISON OF THREE DIFFERENT TISSUE-TO-PLASMA PARTITION COEFFICIENTS: Kp, Kp,u, AND Kp,uu , 2006, Drug Metabolism and Disposition.

[45]  Aleksandra Galetin,et al.  PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITION , 2006, Drug Metabolism and Disposition.

[46]  J. Houston,et al.  The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.

[47]  A. Rostami-Hodjegan,et al.  'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. , 2004, Drug discovery today. Technologies.

[48]  R. Kim,et al.  Genetic variability in CYP3A5 and its possible consequences. , 2004, Pharmacogenomics.

[49]  Terry A Jacobson,et al.  Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. , 2004, The American journal of cardiology.

[50]  Martin M. Schumacher,et al.  In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. , 2004, British journal of clinical pharmacology.

[51]  A. Racine‐Poon,et al.  Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  C. Huber,et al.  Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia , 2003, British Journal of Cancer.

[53]  L. Ereshefsky,et al.  Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone , 2003, Journal of clinical pharmacology.

[54]  Kiyomi Ito,et al.  Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[55]  Yuichi Sugiyama,et al.  Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? , 2002, AAPS PharmSci.

[56]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[57]  J. Miners,et al.  Nonspecific binding of drugs to human liver microsomes. , 2000, British journal of clinical pharmacology.

[58]  D. Jones,et al.  Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. , 1999, The Journal of pharmacology and experimental therapeutics.

[59]  P. Neuvonen,et al.  Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations , 1998, Clinical pharmacology and therapy.

[60]  A. Böhmer.  Commentary , 1996, Brain Research Bulletin.

[61]  S. Preskorn,et al.  Drug-drug interactions. , 1996, The Journal of clinical psychiatry.

[62]  F. Scharpf,et al.  Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. , 1996, Arzneimittel-Forschung.

[63]  D E Salazar,et al.  Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. , 1995, Journal of clinical psychopharmacology.

[64]  J. Backman,et al.  Dose of midazolam should be reduced during diltiazem and verapamil treatments. , 1994, British journal of clinical pharmacology.

[65]  A. Hiller,et al.  A potentially hazardous interaction between erythromycin and midazolam. , 1993, Clinical pharmacology and therapeutics.

[66]  D. Luscombe,et al.  Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers. , 1992, British Journal of Clinical Pharmacology.

[67]  J. Kovarik,et al.  Disposition of roxithromycin in patients with normal and severely impaired renal function , 1990, Antimicrobial Agents and Chemotherapy.

[68]  R. Sabo,et al.  Pharmacokinetics of Roxithromycin (RU 965) , 1988, Journal of clinical pharmacology.

[69]  R B Brandt,et al.  Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes. , 1987, Biochemical medicine and metabolic biology.

[70]  S. Ohkuma,et al.  The effects of basic substances and acidic ionophores on the digestion of exogenous and endogenous proteins in mouse peritoneal macrophages , 1986, The Journal of cell biology.

[71]  G. Belz,et al.  Interaction between digoxin and calcium antagonists and antiarrhythmic drugs , 1983, Clinical pharmacology and therapeutics.

[72]  R. Kates,et al.  Verapamil protein binding in patients and in normal subjects , 1981, Clinical pharmacology and therapeutics.

[73]  P. Tulkens,et al.  Commentary. Lysosomotropic agents. , 1974, Biochemical pharmacology.

[74]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[75]  R. Kitz,et al.  Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. , 1962, The Journal of biological chemistry.

[76]  N. Idkaidek.  Interplay of biopharmaceutics, biopharmaceutics drug disposition and salivary excretion classification systems. , 2014, Saudi Pharmaceutical Journal.

[77]  E. Alexandre,et al.  Isolation and culture of primary hepatocytes from resected human liver tissue. , 2010, Methods in molecular biology.

[78]  Peter Lloyd,et al.  Clinical Pharmacokinetics of Imatinib , 2005, Clinical pharmacokinetics.

[79]  D. Kerr,et al.  The effect of verapamil on the pharmacokinetics of adriamycin , 2004, Cancer Chemotherapy and Pharmacology.

[80]  U. Faire,et al.  Pharmacokinetics of verapamil in patients with hypertension , 2004, European Journal of Clinical Pharmacology.

[81]  J. Backman,et al.  A pharmacokinetic interaction between roxithromycin and midazolam , 2004, European Journal of Clinical Pharmacology.

[82]  D. Jaeck,et al.  Influence of Pre-, Intra- and Post-Operative Parameters of Donor Liver on the Outcome of Isolated Human Hepatocytes , 2004, Cell and Tissue Banking.

[83]  K. Dandekar,et al.  Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[84]  R. Silverman.  Mechanism-based enzyme inactivators. , 1995, Methods in enzymology.

[85]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[86]  D. Bloedow,et al.  Pharmacokinetics of diltiazem in selected animal species and human beings. , 1982, The American journal of cardiology.